Ting Liu

Ting Liu

Auto-generated profile, based on publicly available information

Ting Liu

Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
YLYuli Lin
Yuli Lin
LXLiuling Xiao
Liuling Xiao
QCQian Cai
Qian Cai
CZCuisong Zhu
Cuisong Zhu
SLShufen Li
Shufen Li
RHRui He
Rui He
Chemerin restricts cold-induced IL-33 production by beige adipocytes, impairing beige fat’s ability to dissipate excess energy stores.

22 October 2024 in Journal of Advanced Research
Verified
Journal Article
Open access
YLYu-Lin Li
Yu-Lin Li
BCBo-Yan Chen
Bo-Yan Chen
ZFZe-Hao Feng
Ze-Hao Feng
LZLu-Jun Zhou
Lu-Jun Zhou
TLTing Liu
Ting Liu
DSDuan Sheng-Zhong
Duan Sheng-Zhong
The significance of oral/gut microbiota in acute myocardial infarction (AMI) has been increasingly appreciated. However, correlations between oral/gut microbiota and AMI parameter, as well as the key microbiota that may have a crucial function in this process, remain unclear. To investigate the composition and structure of oral and gut microbiota associated with AMI and explore the roles of specific bacterial species in the progression of AMI. We conducted a case-control study with 37 AMI patients and 36 controls. Oral and gut sample were collected and sequenced. Using correlation analysis, we combined bioinformatics data with AMI clinical parameters and obtained heatmaps of correlation coefficients. Additionally, we used antibiotics to eliminate the gut microbiota of C57BL/6J mice, followed by the transplantation of selected bacteria to verify the gut colonization of oral bacteria and their impact on AMI. The component of oral and gut microbiota of AMI group showed significant alterations when compared to the control group. 17 salivary genera, 21 subgingival genera, and 8 gut genera in AMI group substantially differed from those in control group. Additionally, 19 genera from saliva, 19 genera from subgingival plaque, and 11 genera from feces substantially correlated with AMI clinical parameters. Orally administrated S.o (Streptococcus oralis subsp. dentisani), S.p (Streptococcus parasanguinis), and S.s (Streptococcus salivarius) were able to colonize in the gut and exacerbate myocardial infarction. There is a strong correlation between oral/gut microbiota and AMI. Streptococcus spp. is capable to transmit from oral to gut and exacerbate myocardial infarction in mice. Monitoring and control of specific oral microbiota may be an effective new strategy for improving the therapy of AMI.